

North Central Cancer Treatment Group

N0821, A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age  $\geq 70$  yrs) with Good Performance Status (PS  $< 2$ )

Status Change – October 1, 2010

**NOTICE OF STATUS CHANGE**

The accrual objective for this study has been met. Therefore, this study is permanently closed to patient accrual effective October 1, 2010. Patient entry will not be permitted after Thursday, September 30, 2010 at 4:30 CST. Patients currently on study should be followed according to the protocol.

**Please retain this notice with the protocol.**